NEW YORK, Nov. 28 (GenomeWeb News) - Enzon Pharmaceuticals and Micromet will end their collaboration to identify and develop antibody-based therapeutics for inflammatory and autoimmune diseases, the companies said today.
Registering provides access to this and other free content.
Already have an account?Login Now.
Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.
While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.
In Nature this week: paternal age associated with de novo mutations in children, and more.
Nature News writes that researchers are still wrangling over the role of the p-value.